K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · CHRS
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | CHRS | COHERUS BIOSCIENCES | FOLEY & LARDNER LLP | $50K | Issues related to federal drug reimbursement and domestic manufacturing policy. |
| 2026-04-19 | CHRS | COHERUS BIOSCIENCES INC | INLET STRATEGIES | $60K | Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry |
| 2026-03-09 | CHRS | COHERUS BIOSCIENCES INC. | COHERUS BIOSCIENCES, INC. | $80K | Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response. |
| 2026-01-19 | CHRS | COHERUS BIOSCIENCES | FOLEY & LARDNER LLP | $50K | Issues related to federal drug reimbursement and domestic manufacturing policy. |
| 2026-01-18 | CHRS | COHERUS BIOSCIENCES INC | INLET STRATEGIES | $60K | Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry |
| 2025-10-22 | CHRS | COHERUS BIOSCIENCES INC. | COHERUS BIOSCIENCES, INC. | $80K | Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response. |
| 2025-10-18 | CHRS | COHERUS BIOSCIENCES | FOLEY & LARDNER LLP | $50K | Issues related to federal drug reimbursement and domestic manufacturing policy. |
| 2025-10-15 | CHRS | COHERUS BIOSCIENCES INC | INLET STRATEGIES | $50K | Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry |
| 2025-08-18 | CHRS | COHERUS BIOSCIENCES INC. | COHERUS BIOSCIENCES, INC. | $125K | Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response. |
| 2025-07-21 | CHRS | COHERUS BIOSCIENCES | FOLEY & LARDNER LLP | $50K | Legal and policy advice on federal procurement issues |
| 2025-07-18 | CHRS | COHERUS BIOSCIENCES | FOLEY & LARDNER LLP | $0 | Legal and policy advice on federal procurement issues |
| 2025-07-14 | CHRS | COHERUS BIOSCIENCES INC | INLET STRATEGIES | $45K | Issues related to domestic manufacturing of pharmaceuticals Issues related to the federal governments procurement of Udenyca |
| 2025-04-14 | CHRS | COHERUS BIOSCIENCES INC | INLET STRATEGIES | $45K | Issues related to the federal governments procurement of Udenyca Issues related to the federal governments procurement of Udenyca |
| 2025-03-24 | CHRS | COHERUS BIOSCIENCES INC. | COHERUS BIOSCIENCES, INC. | $65K | Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization |
| 2025-03-24 | CHRS | COHERUS BIOSCIENCES INC. | COHERUS BIOSCIENCES, INC. | $65K | Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response. |